Breast Cancer Clinical Trial

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence

Summary

This phase II trial studies how well telehealth works in improving adherence to endocrine (anti-estrogen) therapy in participants with estrogen receptor and/or progesterone receptor positive (hormone receptor positive) stage 0-III breast cancer who have underwent surgery. Telehealth is an approach to care that uses digital information and communication tools to manage health and well-being. Participants interact with their health care providers via a video chat on a computer or smart phone. Telehealth may help identify the effects of treatment on participants with breast cancer who have underwent surgery.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To evaluate if the utilization of automated patient reported outcomes and follow up Telehealth can improve patient adherence with adjuvant endocrine therapy during the first 12 months of study participation.

II. To evaluate if the utilization of Smart Pill Bottles and follow-up Telehealth encounters can improve patient adherence with adjuvant endocrine therapy during the first 12 months of study participation.

SECONDARY OBJECTIVES:

I. To evaluate if the utilization of automated patient reported outcome and follow-up Telehealth encounters can improve quality of life and decrease side effects while taking adjuvant endocrine therapy.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM I: Patients receive standard of care office visits approximately every 3 months for one year.

ARM II: Patients receive standard of care as in Arm I and 4 automated electronic surveys every 3 weeks (+/- 1 weeks) for a total of 18 electronic surveys over one year. Patients who report severe or very severe side effects, or stopping or are thinking about stopping their endocrine therapy (ET) will have a follow up encounter with a research coordinator.

ARM III: Patients receive a wireless smart pill bottle that performs daily time-specific reminders to open the pill bottle and take the medication. Additional messages are triggered by the pill bottle when non-adherence is indicated (lack of bottle opening or no change in remaining pills), as well as when medication is skipped.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

• Signed informed consent obtained prior to any study specific assessments and procedures

Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Women or men diagnosed with stage 0-III hormone receptor positive (estrogen receptor positive [ER] and /or progesterone receptor [PR] positive) breast cancer

* Staging for eligibility should utilize the most recent American Joint Committee on Cancer (AJCC) breast cancer staging version

Patients (Pts) must have undergone breast surgery for their diagnosis of breast cancer

Adjuvant endocrine therapy has been prescribed by their treating physician

* Patients may receive concurrent adjuvant radiation therapy plus endocrine therapy in the post-operative setting

Have a cell phone with text messaging ability
Have access to a computer, tablet, or smart phone to complete electronic surveys
Patient must be willing to setup an online Jefferson MyChart account
Patients who have been on endocrine therapy for more than 4 years

Exclusion Criteria:

Pts with stage IV metastatic breast cancer
Patients unable to participate in patient portal communication (e.g. do not have either a smart phone, laptop, access to a computer and/ or access to a device with a webcam)
Pts who are non-English speaking and English illiterate

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

285

Study ID:

NCT04054557

Recruitment Status:

Recruiting

Sponsor:

Thomas Jefferson University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Jefferson Health - South Jersey
Washington Township New Jersey, 08080, United States More Info
Maysa Abu-Khalaf, MD
Contact
215-503-5088
Thomas Jefefrson University
Philadelphia Pennsylvania, 19107, United States More Info
Maysa Abu-Khalaf, MD
Contact
215-503-5088
[email protected]
Maysa Abu-Khalaf, MD
Principal Investigator
Methodist Hospital
Philadelphia Pennsylvania, 19148, United States More Info
Allison Zibelli, MD
Contact
215-955-8874
[email protected]
Jefferson Health - Northeast
Torresdale Pennsylvania, 19114, United States More Info
Stefania Nolano, MD
Contact
215-481-4000
[email protected]
Jefferson Health - Asplundh Cancer Pavilion
Willow Grove Pennsylvania, 19090, United States More Info
Allison Zibelli, MD
Contact
215-955-8874
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

285

Study ID:

NCT04054557

Recruitment Status:

Recruiting

Sponsor:


Thomas Jefferson University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider